Cerebral Palsy Alliance Research Institute, Specialty of Child & Adolescent Health, Sydney Medical School, Faculty of Medicine & Health, The University of Sydney, Sydney, NSW, Australia.
Specialty of Child & Adolescent Health, Sydney Medical School, Faculty of Medicine & Health, The University of Sydney, Sydney, NSW, Australia.
Pediatrics. 2022 Jun 1;149(6). doi: 10.1542/peds.2021-055061.
Bobath therapy, or neurodevelopmental therapy (NDT) is widely practiced despite evidence other interventions are more effective in cerebral palsy (CP). The objective is to determine the efficacy of NDT in children and infants with CP or high risk of CP.
Cumulative Index to Nursing and Allied Health Literature, Cochrane Library, Embase, and Medline were searched through March 2021. Randomized controlled trials comparing NDT with any or no intervention were included. Meta-analysis was conducted with standardized mean differences calculated. Quality was assessed by using Cochrane Risk of Bias tool-2 and certainty by using Grading of Recommendations Assessment, Development, and Evaluation.
Of 667 records screened, 34 studies (in 35 publications, 1332 participants) met inclusion. Four meta-analyses were conducted assessing motor function. We found no effect between NDT and control (pooled effect size 0.13 [-0.20 to 0.46]), a moderate effect favoring activity-based approaches (0.76 [0.12 to 1.40]) and body function and structures (0.77 [0.19 to 1.35]) over NDT and no effect between higher- and lower-dose NDT (0.32 [-0.11 to 0.75]). A strong recommendation against the use of NDT at any dose was made. Studies were not all Consolidated Standards of Reporting Trials-compliant. NDT versus activity-based comparator had considerable heterogeneity (I2 = 80%) reflecting varied measures.
We found that activity-based and body structure and function interventions are more effective than NDT for improving motor function, NDT is no more effective than control, and higher-dose NDT is not more effective than lower-dose. Deimplementation of NDT in CP is required.
Bobath 疗法,也称神经发育疗法(NDT),尽管有证据表明其他干预措施在脑瘫(CP)中更有效,但仍广泛应用。本研究旨在确定 NDT 对 CP 或有 CP 高危因素的儿童和婴儿的疗效。
通过 Cumulative Index to Nursing and Allied Health Literature、Cochrane Library、Embase 和 Medline 检索截至 2021 年 3 月的文献。纳入比较 NDT 与任何干预或无干预的随机对照试验。采用标准化均数差计算进行荟萃分析。采用 Cochrane 偏倚风险工具-2 评估质量,采用 Grading of Recommendations Assessment, Development, and Evaluation 评估确定性。
共筛选出 667 条记录,其中 34 项研究(35 篇文献,1332 名参与者)符合纳入标准。进行了 4 项荟萃分析以评估运动功能。我们发现 NDT 与对照组之间无差异(合并效应量 0.13[-0.20 至 0.46]),活动为基础的方法(0.76[0.12 至 1.40])和身体功能与结构(0.77[0.19 至 1.35])更有效,NDT 高剂量与低剂量之间无差异(0.32[-0.11 至 0.75])。强烈建议不要使用任何剂量的 NDT。并非所有研究均符合 CONSORT 报告标准。NDT 与活动为基础的对照比较存在较大异质性(I2=80%),反映了不同的措施。
我们发现,与 NDT 相比,以活动为基础的干预措施和身体结构与功能干预措施更能有效改善运动功能,NDT 与对照组相比无差异,高剂量 NDT 与低剂量 NDT 相比无差异。CP 中应停止使用 NDT。